Grufity logoGrufity logo

TEVA

8.87USD+0.07(+0.80%)Market Closed

Teva Pharmaceutical Industries Ltd

Market Summary

USD8.87+0.07Market Closed
0.80%

TEVA Stock Price

RSI Chart

Valuation

Market Cap

9.9B

Price/Earnings

-9.38

Price/Sales

0.64

Price/Cashflow

9.34

MarketCap/EBT

-5.14

Price/Sales

Profitability

EBT Margin

-12.47%

Return on Equity

-11.66%

Return on Assets

-2.29%

Fundamentals

Revenue

Revenue (TTM)

15.4B

Revenue Y/Y

-3.17%

Revenue Q/Q

3.41%

Earnings

Earnings (TTM)

-1.1B

Earnings Y/Y

-212.08%

Earnings Q/Q

75.71%

Price Action

52 Week Range

6.7811.34
(Low)(High)

Last 7 days

1.7%

Last 30 days

1.8%

Last 90 days

-7.5%

Trailing 12 Months

2.2%

Financial Health

Current Ratio

1.11

Investor Care

Shares Dilution (1Y)

0.63%

Diluted EPS (TTM)

-0.95

Peers (Alternatives to Teva Pharmaceutical Industries)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
459.8B
96.0B
2.92% 12.79%
24
4.79
5.02% 7.14%
342.0B
29.2B
2.35% 41.31%
60.08
11.76
5.34% 1.02%
266.2B
99.7B
7.75% -0.16%
9.08
2.63
43.92% 53.21%
255.3B
57.2B
9.24% 35.23%
15.4
4.47
35.88% 197.59%
163.4B
46.7B
6.43% 43.81%
24.47
3.5
2.79% 223.53%
MID-CAP
5.5B
4.4B
-18.01% -13.37%
-46.93
1.26
1.80% 57.67%
SMALL-CAP
1.9B
628.4M
4.90% -64.68%
-4.08
3.1
64.35% -18.14%
1.9B
659.0M
1.88% 10.24%
32.36
2.95
16.78% -53.92%
1.5B
-
15.46% -69.17%
-0.54
1.95
-4.11% -144.36%
1.2B
112.7M
0.32% -34.93%
-10.75
7.76
-54.94% 40.20%
1.1B
3.1M
10.32% -57.54%
-3.57
108.75
-77.09% -12.24%
1.0B
23.5M
6.37% 30.82%
-12.31
166.87
243.57% -1.04%
945.9M
373.2M
-3.41% -23.70%
4.56
2.34
-0.39% -38.45%
283.2M
49.7M
-18.16% -56.10%
-8.71
5.67
28.95% 32.80%
68.8M
2.6B
-43.99% -88.43%
-0.03
0.02
-13.88% -4855.92%

Financials for Teva Pharmaceutical Industries

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue-0.8%15,43415,55815,87816,23316,324
Gross Profit-1.1%7,3787,4577,5947,5937,651
  S&GA Expenses-0.9%2,4062,4272,4292,4802,488
  R&D Expenses-32.4%146216
Earnings Before Taxes-321.9%-1,924.00-456.00658971-3,870.00
Net Income-71.4%-1,054.00-615.00417726-3,915.00
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-2.4%45,93247,05947,66647,85149,195
  Current Assets-2.3%12,16412,45112,57312,15412,822
    Cash Equivalents-5.4%2,0582,1752,1652,0452,436
  Inventory0.9%4,0494,0123,8184,1674,362
  Net PPE-3.2%5,7405,9325,9826,0406,127
  Goodwill-5.7%18,83719,98620,04020,17920,421
Liabilities-1.9%36,10336,79936,42236,40037,884
  Current Liabilities-5.3%10,99611,61311,02711,82512,691
    LT Debt, Current-17.4%1,6962,0541,4032,3863,507
Shareholder's Equity-3.3%9,0379,34410,27810,46710,324
  Retained Earnings-2.0%-11,716.00-11,484.00-10,529.00-10,370.00-10,662.00
  Additional Paid-In Capital0.1%27,62527,58727,56127,52927,503
Accumulated Depreciation-5,241----
Shares Outstanding0.3%1,1101,1071,1031,1031,103
Minority Interest-13.6%791916966984987
Float-9,550----
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-8.2%1,0591,154798673451
  Share Based Compensation8.9%122112119124127
Cashflow From Investing-25.6%8751,1761,5231,4181,287
Cashflow From Financing-20.1%-2,014.00-1,677.00-2,172.00-1,796.00-1,676.00

Risks

What is the probability of a big loss on TEVA?

100%


Probability that Teva Pharmaceutical Industries stock will be more than 20% underwater in next one year

91.9%


Probability that Teva Pharmaceutical Industries stock will be more than 30% underwater in next one year.

50%


Probability that Teva Pharmaceutical Industries stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TEVA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Teva Pharmaceutical Industries was unfortunately bought at previous high price.

Returns

Cumulative Returns on TEVA

-12.9%


10-Year Cumulative Returns

-23.8%


7-Year Cumulative Returns

-8.2%


5-Year Cumulative Returns

-3.5%


3-Year Cumulative Returns

What are the long-term rolling returns for TEVA?

FIve years rolling returns for Teva Pharmaceutical Industries.

Which funds bought or sold TEVA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
320,000
9,703,000
0.02%
2022-11-21
Parallax Volatility Advisers, L.P.
ADDED
126.69
5,678,000
9,641,000
0.01%
2022-11-18
National Pension Service
UNCHANGED
-
1,000
17,000
-%
2022-11-16
Front Row Advisors LLC
NEW
-
2,000
2,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-21,000
-
-%
2022-11-15
Oxler Private Wealth LLC
UNCHANGED
-
385
5,649
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
15.92
2,067,450
10,539,900
0.02%
2022-11-15
HARBOUR INVESTMENTS, INC.
UNCHANGED
-
-
5,000
-%
2022-11-15
AIMZ Investment Advisors, LLC
REDUCED
-0.36
129,000
1,998,000
1.01%
2022-11-15
STATE STREET CORP
ADDED
7.63
16,137,000
120,259,000
0.01%

1–10 of 39

Latest Funds Activity

Are funds buying TEVA calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own TEVA

Teva Pharmaceutical Industries News

Skegness Siren

Breath-actuated Pressurized Inhaler Market Booming Worldwide With Leading Key Players -Glenmark Pharmaceuticals, Novartis International AG, Propeller Health, AstraZeneca Plc, Philips Respironics, Teva Pharmaceutical Industries, Opko Health, Merck, Bi.19 hours ago

TEVA Fair Value

Recent SEC filings of Teva Pharmaceutical Industries

View All Filings
Date Filed Form Type Document
Nov 21, 2022
8-K
Current Report
Nov 07, 2022
4
Insider Trading
Nov 03, 2022
8-K
Current Report
Nov 03, 2022
10-Q
Quarterly Report
Nov 02, 2022
4
Insider Trading
Aug 24, 2022
4
Insider Trading

Latest Insider Trading transactions for TEVA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-04
Zaks Tal Zvi
ACQUIRED
-
-
12,205
-
2022-11-01
Schultz Kare
ACQUIRED
-
-
116,389
President and CEO
2022-08-22
Kalif Eliyahu Sharon
SOLD
-558,696
10.0666
-55,500
EVP, Chief Financial Officer
2022-08-10
Shani Eli
ACQUIRED
-
-
1,581
EVP,Global Marketing&Portfolio
2022-07-28
Stark David Matthew
SOLD
-525,590
9.0365
-58,163
Exec. VP Chief Legal Officer
2022-06-14
BARER SOL J
ACQUIRED
-
-
25,791
-
2022-06-14
Peres Nechemia Jacob
ACQUIRED
-
-
14,479
-
2022-06-14
Elstein Amir
ACQUIRED
-
-
14,479
-
2022-06-14
Crane Rosemary A
ACQUIRED
-
-
14,479
-
2022-06-14
LIEBERMAN GERALD M
ACQUIRED
-
-
14,479
-

1–10 of 50

KÃ¥re Schultz
37500
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

TEVA Income Statement

2022-09-30
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Net revenues$ 3,595$ 3,887$ 11,041$ 11,778
Cost of sales1,9262,0935,8396,234
Gross profit1,6691,7945,2035,544
Research and development expenses175222628723
Selling and marketing expenses5395971,7161,798
General and administrative expenses283291892822
Intangible assets impairments2421223295
Goodwill impairment007450
Other assets impairments, restructuring and other items3662282227
Legal settlements and loss contingencies19532,048113
Other income(2)(25)(88)(73)
Operating income (loss)419623(1,244)1,638
Financial expenses, net252241721805
Income (loss) before income taxes166382(1,964)833
Income taxes (benefit)10776(792)235
Share in (profits) losses of associated companies, net15(20)(9)
Net income (loss)58302(1,152)608
Net income (loss) attributable to non-controlling interests311(21)32
Net income (loss) attributable to Teva$ 56$ 292$ (1,132)$ 576
Earnings (loss) per share attributable to ordinary shareholders:    
Basic$ 0.05$ 0.26$ (1.02)$ 0.52
Diluted$ 0.05$ 0.26$ (1.02)$ 0.52
Weighted average number of shares (in millions):    
Basic1,1111,1031,1091,102
Diluted1,1191,1091,1091,109

TEVA Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 2,225$ 2,165
Accounts receivables, net of allowance for credit losses of $94 million and $90 million as of September 30, 2022 and December 31, 20213,7304,529
Inventories3,8593,818
Prepaid expenses1,0451,075
Other current assets579965
Assets held for sale1619
Total current assets11,45312,573
Deferred income taxes1,546596
Other non-current assets438515
Property, plant and equipment, net5,5685,982
Operating lease right-of-use assets422495
Identifiable intangible assets, net6,3937,466
Goodwill[1]18,43320,040
Total assets44,25247,666
Current liabilities:  
Short-term debt2,7691,426
Sales reserves and allowances3,6484,241
Accounts payables1,6351,686
Employee-related obligations496563
Accrued expenses2,0412,208
Other current liabilities945903
Total current liabilities11,53411,027
Long-term liabilities:  
Deferred income taxes503784
Other taxes and long-term liabilities3,8462,578
Senior notes and loans18,49721,617
Operating lease liabilities354416
Total long-term liabilities23,20025,395
Commitments and contingencies, see note 10
Total liabilities34,73436,422
Teva shareholders' equity:  
Ordinary shares of NIS 0.10 par value per share; September 30, 2022 and December 31, 2021: authorized 2,495 million shares; issued 1,216 million shares and 1,209 million shares, respectively.5757
Additional paid-in capital27,65227,561
Accumulated deficit(11,660)(10,529)
Accumulated other comprehensive loss(3,153)(2,683)
Treasury shares as of September 30, 2022 and December 31, 2021: 106 million ordinary shares(4,128)(4,128)
Stockholders' equity attributable to Teva shareholders8,76710,278
Non-controlling interests751966
Total equity9,51911,244
Total liabilities and equity$ 44,252$ 47,666
[1]Accumulated goodwill impairment as of September 30, 2022 and December 31, 2021 was approximately $26.3 billion and $25.6 billion, respectively.